These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 7919453

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. What is the effect of adjusting epirubicin doses for body surface area?
    Dobbs NA, Twelves CJ.
    Br J Cancer; 1998 Sep; 78(5):662-6. PubMed ID: 9744507
    [Abstract] [Full Text] [Related]

  • 4. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity.
    Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, Mackey JR, Kuzma M, Damaraju VL, Sawyer MB.
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):93-101. PubMed ID: 20204364
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: derivation of dosing weight ("pharmacokinetic mass").
    Shibutani K, Inchiosa MA, Sawada K, Bairamian M.
    Anesthesiology; 2004 Sep; 101(3):603-13. PubMed ID: 15329584
    [Abstract] [Full Text] [Related]

  • 7. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
    Basser RL, Sobol MM, Duggan G, Cebon J, Rosenthal MA, Mihaly G, Green MD.
    J Clin Oncol; 1994 Aug; 12(8):1659-66. PubMed ID: 8040678
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
    Hunz M, Jetter A, Warm M, Pantke E, Tuscher M, Hempel G, Jaehde U, Untch M, Kurbacher C, Fuhr U.
    Clin Pharmacol Ther; 2007 May; 81(5):659-68. PubMed ID: 17301739
    [Abstract] [Full Text] [Related]

  • 10. Clinical pharmacokinetics of epirubicin.
    Robert J.
    Clin Pharmacokinet; 1994 Jun; 26(6):428-38. PubMed ID: 8070217
    [Abstract] [Full Text] [Related]

  • 11. Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats.
    Simonsen LE, Wählby U, Sandström M, Freijs A, Karlsson MO.
    Anticancer Res; 2000 Jun; 20(3A):1519-25. PubMed ID: 10928065
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer.
    Jakobsen P, Steiness E, Bastholt L, Dalmark M, Lorenzen A, Petersen D, Gjedde SB, Sandberg E, Rose C, Nielsen OS.
    Cancer Chemother Pharmacol; 1991 Jun; 28(1):63-8. PubMed ID: 2040035
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Interaction of epirubicin with other cytotoxics and anti-emetic drugs.
    Zhang W, Zalcberg JR, Cosolo W.
    Anticancer Drugs; 1992 Dec; 3(6):593-7. PubMed ID: 1288730
    [Abstract] [Full Text] [Related]

  • 18. Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin).
    Eksborg S.
    Acta Oncol; 1990 Dec; 29(3):339-42. PubMed ID: 2363946
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.